BRIEF—$12.5 million seed funding for Seamless Therapeutics

A new gene editing company, Seamless Therapeutics, has launched in Germany with $12.5 million in seed financing from investors including Wellington Partners and Forbion.

The company is working on a novel recombinase platform, with the goal of developing therapeutics to transform the treatment of severe diseases.

The money will be used to further advance the company’s proprietary technology, and to expand in Europe and the USA.

The foundational research behind the company comes from scientists working at the University Cancer Center of the Technische Universität Dresden.

Chief scientific officer Felix Lansing said the firm’s modular platform has “succeeded in reprogramming site-specific recombinases to any given target sequence,” opening up the potential for a “best-in-class gene editing system to treat human disease.”